Russell Investments Group
AST

Russell Investments Group’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Russell Investments Group’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-22,144
Closed -$75K – 3169
2017
Q1 		$75K Hold
22,144
– – ﹤0.01% 2856
2016
Q4 		$102K Buy
+22,144
New +$91.4K ﹤0.01% 2876

Other funds holding AST

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Russell Investments Group's AST Position: Q2 2017 in Review

Russell Investments Group sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q2 2017, closing a stake of 22,144 shares — an estimated $75K sold.

Russell Investments Group first reported a position in AST in Q4 2016 and held it in 2 quarters. The position peaked at $102K in Q4 2016. 64 funds tracked by Wall St. Rank hold AST as of Q2 2017.

  • Russell Investments Group reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q2 2017 after selling out during the quarter.
  • Russell Investments Group sold 22,144 Asterias Biotherapeutics Inc. Series A shares in Q2 2017, an estimated $75K.
  • Russell Investments Group first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2016 and held it in 2 quarters.
  • Russell Investments Group's Asterias Biotherapeutics Inc. Series A position peaked at $102K in Q4 2016.
  • 64 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q2 2017.

Based on Russell Investments Group's 13F filing for Q2 2017, filed 25 Jul 2017.